Bayer has received MHRA approval for Kerendia (finerenone) for adults in the UK with symptomatic chronic heart failure and a left ventricular ejection fraction of 40% or above. Th ...

Transgene has completed patient randomisation in the phase 2 part of its phase 1/2 clinical trial evaluating TG4050, an individualised neoantigen therapeutic vaccine being developed for the adjuvant ...

Funding to accelerate development of AI-driven tumour profiling tool OneMap One Biosciences has secured €15 million in Series A financing to expand its AI-powered single-cell transcriptomic platform, ...

Early-stage study reveals strong immune response and safety profile for ACI-35.030 AC Immune SA has announced peer-reviewed results from its phase 1b/2a trial of two Tau-targeting active ...

A British inquiry into the use of chemotherapy to treat seriously ill cancer patients has found the treatment caused or hastened death in 27% of cases. A British inquiry into the use of chemotherapy ...

AlzeCure Pharma has released new preclinical findings for its lead Alzheimer’s drug candidate, NeuroRestore ACD856, following a presentation at the AD/PD 2026 international conference. The full ...

New funding will support the phase 2 expansion trial of THEO-260 The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025.

Regulator recommends durvalumab as first perioperative IO option for muscle‑invasive disease AstraZeneca has received a positive recommendation from the National Institute for Health and Care ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled COPD of an eosinophilic phenotype who are already receiving triple therapy ...

Positive safety and pharmacokinetic data lay foundation for phase 2 study in 2026 Herantis Pharma has announced positive topline results from its phase 1b trial of HER-096 in people living with ...

Conditional marketing authorisation granted for the treatment of recurrent or advanced endometrial cancer GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and ...

Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...